Calycosin down-regulates c-Met to suppress development of glioblastomas

被引:11
|
作者
Nie, Xiaohu [1 ]
Zhou, Yue [1 ]
Li, Xiaobing [1 ]
Xu, Jie [1 ]
Pan, Xuyan [1 ]
Yin, Rui [1 ]
Lu, Bin [1 ]
机构
[1] Huzhou Cent Hosp, Dept Neurosurg, Huzhou, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
AKT; calycosin; c-Met; glioblastoma; MMP9; SIGNALING PATHWAY; RECEPTOR; CANCER; INHIBITION; EXPRESSION; APOPTOSIS; MIGRATION; PI3K/AKT; SURVIVAL; INVASION;
D O I
10.1007/s12038-019-9904-4
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The antitumor effect of calycosin has been widely studied, but the targets of calycosin against glioblastomas are still unclear. In this study we focused on revealing c-Met as a potential target of calycosin suppressing glioblastomas. In this study, suppressed-cell proliferation and cell invasion together with induced-cell apoptosis appeared in calycosin-treated U251 and U87 cells. Under treatment of calycosin, the mRNA expression levels of Dtk, c-Met, Lyn and PYK2 were observed in U87 cells. Meanwhile a western blot assay showed that c-Met together with matrix metalloproteinases-9 (MMP9) and phosphorylation of the serine/threonine kinase AKT (p-AKT) was significantly down-regulated by calycosin. Furthermore, overexpressed c-Met in U87 enhanced the expression level of MMP9 and p-AKT and also improved cell invasion. Additionally, the expression levels of c-Met, MMP9 and p-AKT were inhibited by calycosin in c-Met overexpressed cells. However, an AKT inhibitor (LY294002) only effected on MMP9 and p-AKT, not on c-Met. These data collectively indicated that calycosin possibility targeting on c-Met and exert an anti-tumor role via MMP9 and AKT.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding
    Park, Kyung Chan
    Geleta, Bekesho
    Leck, Lionel Yi Wen
    Paluncic, Jasmina
    Chiang, Shannon
    Jansson, Patric J.
    Kovacevic, Zaklina
    Richardson, Des R.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2020, 295 (02) : 481 - 503
  • [22] Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
    Jiang, Xiufeng
    Feng, Kang
    Zhang, Ye
    Li, Zengyao
    Zhou, Fan
    Dou, Huiqiang
    Wang, Tong
    ONCOTARGET, 2015, 6 (14) : 12340 - 12356
  • [23] BORTEZOMIB PS-341 TREATMENT DOWN-REGULATES TENASCIN C IN PBMNC
    Moussa, Omar
    Bradley, Emma
    Twomblet, Katherine E.
    TISSUE ANTIGENS, 2015, 85 (05): : 381 - 381
  • [24] Helicobacter pylori Infection down-regulates GDDR, leading to gastric cancer development
    Zhao, Zhanwei
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 507 - 507
  • [25] Activation of protein kinase C down-regulates glial but not neuronal taurine uptake
    TchoumkeuNzouessa, GC
    Rebel, G
    NEUROSCIENCE LETTERS, 1996, 206 (01) : 61 - 64
  • [26] Infection with Hepatitis C down-regulates the expression of cytokine genes in peripheral blood
    Taylor, Milton W.
    Bolen, Christopher R.
    Kleinstein, Steven H.
    Brodsky, Leonid
    CYTOKINE, 2011, 56 (01) : 94 - 94
  • [27] C-MET as a new therapeutic target for the development of novel anticancer drugs
    Israel Cañadas
    Federico Rojo
    Montserrat Arumí-Uría
    Ana Rovira
    Joan Albanell
    Edurne Arriola
    Clinical and Translational Oncology, 2010, 12 : 253 - 260
  • [28] Soy protein isolate down-regulates caveolin-1 expression to suppress osteoblastic cell senescence pathways
    Zhang, Jian
    Lazarenko, Oxana P.
    Blackburn, Michael L.
    Badger, Thomas M.
    Ronis, Martin J. J.
    Chen, Jin-Ran
    FASEB JOURNAL, 2014, 28 (07): : 3134 - 3145
  • [29] HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
    Shao, Zhiwei
    Pan, Haoqi
    Tu, Sheng
    Zhang, Jingying
    Yan, Sheng
    Shao, Anwen
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [30] C-MET as a new therapeutic target for the development of novel anticancer drugs
    Canadas, Israel
    Rojo, Federico
    Arumi-Uria, Montserrat
    Rovira, Ana
    Albanell, Joan
    Arriola, Edurne
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (04): : 253 - 260